HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Nakabayashi, H Articles by Shimizu, K Search for Related Content PubMed PubMed Citation Articles by Nakabayashi, H Articles by Shimizu, K Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Brain Cancer

Prognostic significance of CDC25B expression in gliomas

¹ Department of Neurosurgery, Kochi University, Kochi Medical School, Kochi, Japan
² Department of Neurosurgery, Osaka City University, Medical School, Osaka, Japan

Correspondence to:
Dr H Nakabayashi
Department of Neurosurgery, Kochi University, Kochi Medical School, Kohasu, Oko-cho, Nankoku 783-8505, Japan; nakarinh{at}med.kochi-u.ac.jp Background: CDC25B is a cell-cycle regulatory protein, which is considered to be related to tumorigenesis and progression of tumours.

Aims: To elucidate the role of CDC25B in glioma, the expression of CDC25B and the association of the CDC25B expression with the clinicopathological parameters were investigated.

Methods: Fifty seven gliomas, which included 21 low-grade astrocytomas, 17 anaplastic astrocytomas and 19 glioblastomas, were studied. Protein expressions of CDC25B were evaluated by immunohistochemical methods. Semiquantitative and real-time RT-PCR analyses for the expression of CDC25B mRNA were also carried out. Disease-free survival (DFS) data were analysed by using the Kaplan–Meier method.

Results: High expression of CDC25B was identified in 18 of the 19 glioblastomas, in 10 of the 17 anaplastic astrocytomas, but not in any of the 21 low-grade astrocytomas. The CDC25B mRNA expression increased with the rise in histological grade. Increased CDC25B expression was correlated significantly with a shorter period of DFS, as shown by multivariate analysis.

Conclusions: Patients with an unfavourable clinical outcome are characterised by the increased expression of CDC25B in their glioma samples. Useful clinical information, especially on its relevance as a prognostic indicator, is provided by the evaluation of CDC25B expression in gliomas.

Abbreviations: DFS, disease-free survival; GAPDH, glyceraldehyde-3-phosphate dehydrogenase